Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi IP to GeneDesign

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said today it has granted a non-exclusive license to the Kreutzer-Limmer family of RNAi patents to GeneDesign, a Japanese supplier of siRNAs.
Under the terms of the agreement, GeneDesign has gained the right to provide RNAi research products and services under the patent family, which covers siRNAs and their use in mediating RNAi in mammalian cells.
GeneDesign's president, Kazuhiko Yuyama, said the license to this patent estate "allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace in Asia."
Alnylam's VP of business development, Jason Rhodes, said it now has licensed the IP to three research products suppliers in Asia, and 15 suppliers worldwide.
“We believe that the vast majority of industrial sales of siRNAs for research purposes globally are currently being made under access to Alnylam's intellectual property," Rhodes said.
Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.